Annexon, Inc. – NASDAQ:ANNX
Annexon stock price today
$2.19
-3.00
-57.8%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in 2 minutes
Annexon stock price monthly change
-14.64%
month
Annexon stock price quarterly change
-14.64%
quarter
Annexon stock price yearly change
+12.10%
year
Annexon key metrics
Market Cap | 535.63M |
Enterprise value | 150.89M |
P/E | -1.7 |
EV/Sales | N/A |
EV/EBITDA | -1.10 |
Price/Sales | N/A |
Price/Book | 1.11 |
PEG ratio | -0.07 |
EPS | -1.47 |
Revenue | N/A |
EBITDA | -129.68M |
Income | -120.73M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAnnexon stock price history
Annexon stock forecast
Annexon financial statements
| Jun 2023 | 0 | -35.18M | |
|---|---|---|---|
| Sep 2023 | 0 | -32.48M | |
| Dec 2023 | 4.86M | -27.89M | -573.18% |
| Mar 2024 | 0 | -25.17M |
| Dec 2023 | 4.86M | -27.89M | -573.18% |
|---|---|---|---|
| Mar 2024 | 0 | -25.17M | |
| Oct 2025 | 0 | -33.12M | |
| Dec 2025 | 0 | -34.34M |
Analysts Price target
Financials & Ratios estimates
0%
Yield TTM
| Payout ratio | 0% |
|---|
| 2019 | |
|---|---|
| 2020 | 1.46% |
| 2021 | |
| 2022 | |
| 2023 |
| Jun 2023 | 233013000 | 48.28M | 20.72% |
|---|---|---|---|
| Sep 2023 | 203816000 | 46.97M | 23.05% |
| Dec 2023 | 297674000 | 47.11M | 15.83% |
| Mar 2024 | 304069000 | 41.66M | 13.7% |
| Jun 2023 | -36.38M | 5.53M | 345K |
|---|---|---|---|
| Sep 2023 | -28.29M | 47.83M | 0 |
| Dec 2023 | -23.47M | -2.18M | 117.59M |
| Mar 2024 | -28.26M | -77.30M | 32.41M |
Annexon alternative data
| Aug 2023 | 80 |
|---|---|
| Sep 2023 | 77 |
| Oct 2023 | 77 |
| Nov 2023 | 77 |
| Dec 2023 | 76 |
| Jan 2024 | 76 |
| Feb 2024 | 76 |
| Mar 2024 | 71 |
| Apr 2024 | 71 |
| May 2024 | 71 |
| Jun 2024 | 70 |
| Jul 2024 | 70 |
Annexon other data
100.00%
+0.40%
of ANNX is owned by hedge funds
47.36M
+8.94M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Feb 2024 | 0 | 17898 |
| Apr 2024 | 3200 | 0 |
| May 2024 | 3200 | 0 |
| Jun 2024 | 3200 | 0 |
| Jul 2024 | 3200 | 2994 |
| Aug 2024 | 3200 | 5500 |
| Sep 2024 | 3200 | 15500 |
| Oct 2024 | 3200 | 5408 |
| Dec 2024 | 3200 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | CARSON WILLIAM H. director | Common Stock | 3,200 | $5.33 | $17,056 | ||
Option | LOVE DOUGLAS director, officer.. | Common Stock | 36,050 | $1.85 | $66,693 | ||
Option | LOVE DOUGLAS director, officer.. | Common Stock | 78,399 | $1.85 | $145,038 | ||
Option | LOVE DOUGLAS director, officer.. | Stock Option (Right to Buy) | 36,050 | $1.85 | $66,693 | ||
Option | YEDNOCK TED officer: EVP & CH.. | Common Stock | 5,408 | $1.85 | $10,005 | ||
Sale | YEDNOCK TED officer: EVP & CH.. | Common Stock | 5,408 | $7.41 | $40,073 | ||
Option | YEDNOCK TED officer: EVP & CH.. | Stock Option (Right to Buy) | 5,408 | $1.85 | $10,005 | ||
Purchase | CARSON WILLIAM H. director | Common Stock | 3,200 | $5.97 | $19,104 | ||
Sale | YEDNOCK TED officer: EVP & CH.. | Common Stock | 4,500 | $7.1 | $31,950 | ||
Sale | YEDNOCK TED officer: EVP & CH.. | Common Stock | 5,500 | $6.16 | $33,880 |
| Patent |
|---|
Application Filling date: 19 Jul 2021 Issue date: 17 Feb 2022 |
Application Filling date: 10 Feb 2021 Issue date: 9 Sep 2021 |
Application Filling date: 8 Apr 2020 Issue date: 22 Apr 2021 |
Grant Filling date: 6 Feb 2020 Issue date: 23 Feb 2021 |
Application Filling date: 25 Jun 2020 Issue date: 8 Oct 2020 |
Application Filling date: 6 Feb 2020 Issue date: 30 Jul 2020 |
Grant Filling date: 23 Nov 2016 Issue date: 28 Jul 2020 |
Application Filling date: 1 Nov 2019 Issue date: 7 May 2020 |
Grant Filling date: 4 Jan 2019 Issue date: 17 Mar 2020 |
Application Filling date: 17 May 2019 Issue date: 17 Oct 2019 |
| Insider | Compensation |
|---|---|
| Mr. Douglas Love J.D., Esq. (1968) Chief Executive Officer, Pres & Director | $709,670 |
| Dr. Ted Yednock Ph.D. (1958) Executive Vice President, Chief Innovation Officer & Chairman of the Scientific Advisory Board | $525,430 |
Mr. Michael Overdorf M.B.A. (1970) Executive Vice President & Chief Bus. Officer | $398,770 |
Annexon: With IGOS Study Completion, Pre-BLA Meeting In 1st Half 2025 On Deck
Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place
Annexon: ANX007 Advances Forward With Stellar Endpoint
Annexon: Mixed Results, Overly Strong Market Reaction
May MDA Breakout Stocks/ETFs Week 20 - 2023: High-Frequency Gainers To Give You An Edge
April MDA Breakout Stocks/ETFs Week 17 - 2023: High-Frequency Gainers To Give You An Edge
Annexon: Attractive, Below-Radar, Undervalued Stock
-
What's the price of Annexon stock today?
One share of Annexon stock can currently be purchased for approximately $2.19.
-
When is Annexon's next earnings date?
Unfortunately, Annexon's (ANNX) next earnings date is currently unknown.
-
Does Annexon pay dividends?
No, Annexon does not pay dividends.
-
How much money does Annexon make?
Annexon has a market capitalization of 535.63M.
-
What is Annexon's stock symbol?
Annexon, Inc. is traded on the NASDAQ under the ticker symbol "ANNX".
-
What is Annexon's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Annexon?
Shares of Annexon can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Annexon's key executives?
Annexon's management team includes the following people:
- Mr. Douglas Love J.D., Esq. Chief Executive Officer, Pres & Director(age: 57, pay: $709,670)
- Dr. Ted Yednock Ph.D. Executive Vice President, Chief Innovation Officer & Chairman of the Scientific Advisory Board(age: 67, pay: $525,430)
- Mr. Michael Overdorf M.B.A. Executive Vice President & Chief Bus. Officer(age: 55, pay: $398,770)
-
How many employees does Annexon have?
As Jul 2024, Annexon employs 70 workers, which is 1% less then previous quarter.
-
When Annexon went public?
Annexon, Inc. is publicly traded company for more then 5 years since IPO on 24 Jul 2020.
-
What is Annexon's official website?
The official website for Annexon is annexonbio.com.
-
Where are Annexon's headquarters?
Annexon is headquartered at 1400 Sierra Point Parkway, Brisbane, CA.
-
How can i contact Annexon?
Annexon's mailing address is 1400 Sierra Point Parkway, Brisbane, CA and company can be reached via phone at +65 08225500.
Annexon company profile:
Annexon, Inc.
annexonbio.comExchange:
NASDAQ
Full time employees:
71
Industry:
Biotechnology
Sector:
Healthcare
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.
1400 Sierra Point Parkway
Brisbane, CA 94005
Brisbane, CA 94005
CIK: 0001528115
ISIN: US03589W1027
CUSIP: 03589W102
